Doer Biologics Overview
- Year Founded
-
2014
- Status
-
Acquired/Merged
- Latest Deal Type
-
M&A
- Latest Deal Amount
-
$74.6M
Doer Biologics General Information
Description
Developer and researcher of protein drugs for metabolic diseases, ophthalmology and cancer. The company utilizes xLONGylation which is a recombinant PEG-like polypeptide platform, an activated antibody for precision tumor therapy and a multi-targeted bio-therapeutics that improves drug targeting, safety and simulates highly hydrophilic compounds enabling the development of effective drugs for cancer, metabolic diseases and eye related diseases.
Contact Information
Website
www.doorbio.com(Operating Subsidiary)
Corporate Office
- 2nd Floor, Building 3, Hexiang Technology Center
- Medical Port Town, Qiantang New District
- Hangzhou, Zhejiang
- China
Corporate Office
- 2nd Floor, Building 3, Hexiang Technology Center
- Medical Port Town, Qiantang New District
- Hangzhou, Zhejiang
- China
Doer Biologics Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 3. Merger/Acquisition | 27-Apr-2021 | $74.6M | Completed | Generating Revenue | ||
| 2. Later Stage VC (Series A1) | 03-Nov-2020 | Completed | Generating Revenue | |||
| 1. Early Stage VC (Series A) | 13-Feb-2019 | Completed | Generating Revenue |
Doer Biologics Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Doer Biologics Patents
Doer Biologics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| EP-4282884-A1 | Multi-domain fusion protein and use thereof | Pending | 22-Feb-2021 | ||
| AU-2022221660-A1 | Multi-domain fusion protein and use thereof | Pending | 22-Feb-2021 | ||
| CA-3211427-A1 | Multi-domain fusion protein and use thereof | Pending | 22-Feb-2021 | ||
| EP-4282884-A9 | Multi-domain fusion protein and use thereof | Pending | 22-Feb-2021 | ||
| US-20240124587-A1 | Multi-domain fusion protein and use thereof | Pending | 22-Feb-2021 | C07K16/2818 |
Doer Biologics Former Investors (4)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Haiyue Asset Management | Corporate Venture Capital | Minority | ||
| Hangzhou Bairui Investment | Corporation | Minority | ||
| Kaitai Capital | Venture Capital | Minority | ||
| SinoWisdom | Venture Capital | Minority |
Doer Biologics FAQs
-
When was Doer Biologics founded?
Doer Biologics was founded in 2014.
-
Where is Doer Biologics headquartered?
Doer Biologics is headquartered in Hangzhou, China.
-
What industry is Doer Biologics in?
Doer Biologics’s primary industry is Biotechnology.
-
Is Doer Biologics a private or public company?
Doer Biologics is a Private company.
-
What is the current valuation of Doer Biologics?
The current valuation of Doer Biologics is .
-
What is Doer Biologics’s current revenue?
The current revenue for Doer Biologics is .
-
How much funding has Doer Biologics raised over time?
Doer Biologics has raised $14.9M.
-
Who are Doer Biologics’s investors?
Haiyue Asset Management, Hangzhou Bairui Investment, Kaitai Capital, and SinoWisdom have invested in Doer Biologics.
-
When was Doer Biologics acquired?
Doer Biologics was acquired on 27-Apr-2021.
-
Who acquired Doer Biologics?
Doer Biologics was acquired by Huadong Medicine Company.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »
